MyFinsight
Home
Blog
About
Contact
Download
Download image
Proceeds from sale of
future royalties
$250,000K
Proceeds from marketable
securities
$70,175K
Issuance of common stock
on exercise of...
$8,717K
Issuance of common stock
through employee stock...
$607K
Net cash provided by
financing activities
$178,786K
Net cash provided by
investing activities
$69,959K
Canceled cashflow
$80,538K
Effect of exchange rate
changes on cash and cash...
$98K
Canceled cashflow
$216K
Net change in cash
and cash...
$203,125K
Canceled cashflow
$45,718K
Purchases of common stock
for retirement
$76,151K
Payments for transaction
costs related to sale...
$4,387K
Acquisition of property and
equipment
$216K
Stock-based compensation
expense
$6,935K
Non-cash interest
expense related to sale...
$2,040K
Amortization of operating
lease right-of-use...
$1,708K
Depreciation of property and
equipment
$963K
Amortization of intangible
assets
$176K
Amortization of debt issuance
costs
$26K
Net cash provided
used in operating...
-$45,718K
Canceled cashflow
$11,848K
Net loss
-$44,162K
Accounts payable and
accrued liabilities
-$7,750K
Deferred income tax
recovery
$2,200K
Prepaid expenses and
other current assets
$1,726K
Operating lease
liabilities
-$1,005K
Deferred revenue
-$340K
Unrealized foreign
exchange gain
$331K
Accounts receivable
$36K
Income taxes payable
-$16K
Back
Back
Cash Flow
source: myfinsight.com
Zymeworks Inc. (ZYME)
Zymeworks Inc. (ZYME)